Open in interactive viewer → charts, metric popovers & call review

AMS Grew Revenue 14% and Lost More Money Doing It — and the Language of the Call Changed Hands

Direct patient services keeps compounding, but the keyword deck has flipped from 'operational execution' to lenders, allowances and legal fees, with a Fifth Third forbearance clock running to June 2027 and the stock down 28% in ninety days.
AMS · Earnings Call · 2026-11-12

The Revenue Line Works. The Earnings Line Doesn't.

American Shared Hospital Services won the argument it set out to win years ago: the shift into direct patient services business is real and it is compounding. Third-quarter revenue rose 6.3% to $7.6 million and nine-month revenue 13.7% to $23.1 million, with direct patient services up 27% to $13.5 million over nine months and Medical Equipment Leasing segment revenue holding at roughly $9.6 million — a flat annuity that now funds the growth story rather than being it. Total Gamma Knife facilities in Peru and Ecuador procedures rose about 11% in both periods, helped by the Esprit upgrade. Except the earnings line went the other way. Gross margin fell to 19.9% from 22.1%, and the quarterly net loss widened to $620,000, or $0.09 a share, from $17,000 a year earlier. Over nine months the loss nearly doubled to $1.7 million from $922,000. EBITDA slipped to $1.4 million from $1.9 million. The proximate cause is not clinical: administrative expenses increased to $5.8 million from $5.1 million, and management pinned the delta on legal, banking and consulting work tied to the credit agreement. Gross margin in the last filed quarter was 17.0%, down 25 points over three years and 65% below the 2017 peak of 49.5%. That is the price of the pivot, and it was telegraphed. What was not telegraphed is how long the pivot's overhead would run. Total revenue of $8 million in the last filed quarter was up 19% year over year.

The Language Changed Hands

This is where the quarter gets interesting. Look at what AMS used to talk about and no longer does. In the third quarter of 2025 the deck carried capital structure at a prominent rank and operational execution as a live theme; in the same era there was cash generation, installed base and patient throughput. Those words are aspirational. They describe a company managing for growth. This quarter's top keywords are diagnostic in a different way: increased allowance for credit losses associated with the Rhode Island facilities, the credit agreement with Fifth Third, and financing arrangements requiring "continued attention and execution against specified milestones." "Operational execution" itself now appears on the company's own decliner list — the sharpest conceptual drop of the quarter. When a management team stops leading with execution and starts leading with forbearance, the market hears it. It is the second consecutive quarter of a Rhode Island receivable problem. In August, private investor Anthony Marchese pressed management on a roughly $900,000 accounts receivable charge and complained that “every quarter, there is something. If it is not a center that was closed, it was maintenance, if not maintenance now, it is, you know, accounts receivable.” — Anthony Marchese · 2026-08-13 The answer then was insurance carriers. This quarter the same bucket got topped up again. Receivables ran at 98.7% of revenue in the last filed quarter, down 36.7 points year over year but still near a decade of one-times-revenue readings.

We're in a process of maybe taking 2 steps forward and 1 step backward sometimes it seems.

Raymond Stachowiak, Executive Chairman · 2026-11-12
That is Executive Chairman Ray Stachowiak on Rhode Island, and it is the most honest sentence in the deck. Revenue there is up; procedure volumes are down; the revenue cycle is not converted.

The Clock, and the Chairman's Checkbook

The balance sheet is now the story. Effective net cash was negative $10 million in the last filed quarter, versus positive $3 million in mid-2023. Cash has climbed to $9.5 million from $3.7 million at year-end on $5.8 million of nine-month operating cash flow, but the current portion of long-term debt is $15.7 million. “We have $9.5 million of cash against a $15 million indebtedness with Fifth Third. And we ought to be able to find a solution to that.” — Raymond Stachowiak, Executive Chairman · 2026-11-12 The forbearance runs to June 30, 2027. That was disclosed in August, when Tony Kamin of Eastwood Partners extracted the concession that the amendment also obliges the company to pursue a sale of assets, and Ray answered that AMS is pursuing “any and all options.” — Raymond C. Stachowiak, Executive Chairman · 2026-08-13 Nothing on this call retired that question — it simply got quieter, and the asset-light proton development in Johnston, Rhode Island is precisely where “the asset-light philosophy is being pursued.” — Raymond Stachowiak, Executive Chairman · 2026-11-12 The offsetting signal is insider capital: Stachowiak's new vehicle bought shares from a private investor and injected “$2 million of subordinated financing this past quarter.” — Raymond Stachowiak, Executive Chairman · 2026-11-12 Real money, real confidence — but subordinated debt, ranking behind the bank, and it does not change the covenant math. Meanwhile the buyback door stays shut, as it was in March: “the company has not really been interested in a stock buyback program.” — Raymond Stachowiak, Chief Executive Officer · 2026-03-31

What Would Break the Loop

The bull case is unchanged and it is not crazy: certificates of need for a linear accelerator in Bristol and a proton system in Johnston, a Guadalajara Gamma Knife joint venture expected to treat patients mid-2027 — the single genuinely new forward-looking keyword this quarter, Javier in Guadalajara — and a leasing base still throwing off nine figures of revenue. Price-to-revenue sits at 0.3x, roughly half its level a year ago. The bear case is that the tape already voted. AMS shares are down 27.5% over ninety days, 32.5% off the August 13 peak of $1.60, and 77.3% below the 2017 high — a micro-cap with $7.25 million of market value, negative net cash, and a lender forbearance that expires in nineteen months. Free cash flow less stock comp came in at $2 million, up 187% year over year. So the honest read: revenue is fine, cash generation is fine, and the P&L is being eaten by the cost of being over-levered. “When those costs go away, we resolve our relationship with Fifth Third, we should improve our operating margin levels.” — Raymond Stachowiak, Executive Chairman · 2026-11-12 That is a conditional promise, not guidance — and it is the same conditional promise the last four calls have made in different words. Until the keyword deck flips back from reimbursement trends and lender language to execution and throughput, the growth story is on hold behind the balance sheet.